Related references
Note: Only part of the references are listed.Higher efficacy of sequential therapy with interferon-α and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients
SK Sarin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B
Michalis Economou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
S Iino et al.
JOURNAL OF VIRAL HEPATITIS (2005)
Current treatment of chronic hepatitis B: Benefits and limitations
RP Perrillo
SEMINARS IN LIVER DISEASE (2005)
Molecular virology and the development of resistant mutants: Implications for therapy
S Locarnini
SEMINARS IN LIVER DISEASE (2005)
Clinical trial results of new therapies for HBV: Implications for treatment guidelines
RG Gish
SEMINARS IN LIVER DISEASE (2005)
Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments
SP Hong et al.
JOURNAL OF HEPATOLOGY (2004)
Combination of α-interferon with lamivudine, reduces viral breakthrough during long-term therapy
MK Jang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
M Saruc et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis
JJY Sung et al.
JOURNAL OF HEPATOLOGY (2003)
Thymosin-α1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B
S Sugahara et al.
HEPATOLOGY RESEARCH (2002)
Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
GKK Lau et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study
T Santantonio et al.
JOURNAL OF HEPATOLOGY (2002)
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis
HLY Chan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea
YH Paik et al.
JOURNAL OF HEPATOLOGY (2001)
Thymosin α1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro
CA Baumann et al.
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY (2000)
Hepatitis B genotypes and the response to interferon therapy
JH Kao et al.
JOURNAL OF HEPATOLOGY (2000)
A randomized, controlled study of thymosin-α1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B
C Zavaglia et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
JH Kao et al.
GASTROENTEROLOGY (2000)
Share Paper
